UPDATE: Cantor Fitzgerald Starts Intersect ENT (XENT) at Buy

(Updated - June 29, 2015 4:12 PM EDT)

(update reflect correction in firm name)

Cantor Fitzgerald initiates coverage on Intersect ENT (NASDAQ: XENT) with a Buy rating and a price target of $35.00.

Analyst Caroline Corner commented, "We are initiating coverage of Intersect ENT with a BUY rating and a $35 PT. We believe the company is unique in offering products to comprehensively treat sinusitis by opening, medicating, and maintaining the sinus channels. While other companies have offerings that address these indications individually, we think that Intersect ENT’s proprietary drug delivery via bioabsorbable implant technology offers an elegant solution to sinusitis management. We think Intersect ENT offers a versatile technology platform facing multiple opportunities within the surgical center and physician office treatment of chronic sinusitis. The company held its initial public offering in July 2014."

For an analyst ratings summary and ratings history on Intersect ENT click here. For more ratings news on Intersect ENT click here.

Shares of Intersect ENT closed at $28.65 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Cantor Fitzgerald Starts Materialise NV (MTLS) at Overweight, 'Well-Positioned to meet rising software demand'
• General Motors (GM) PT Raised to $55 at Wedbush
• Incyte (INCY) PT Lowered to $84 at Oppenheimer